Drug class
Interleukin-23 Antagonist
Mechanism of action
Interleukin-23 Antagonists [MoA]
General use cases
- Psoriasis
- adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy
- adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis
- adult patients with moderately to severely active ulcerative colitis
- adult patients with moderately to severely active Crohn's disease
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
